TLSA ▼ -1.4% - Tiziana Life Sciences Ltd $TLSA - Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Sclerosis Treated with Intranasal Foralumab 09-NOV-2026 01:30 PM ET